Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience
Psoriasis is a chronic immune-mediated disease primarily affecting the skin. The most common subtype is plaque psoriasis, which can affect any body area, with a predilection for the knees, elbows, scalp, lumbosacral region, and genitalia. The European guidelines adopted in Italy recommend systemic...
Saved in:
| Main Authors: | Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2024-11-01
|
| Series: | Dermatology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/dr/article/view/10080 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of interleukin-17 inhibitors in psoriasis patients: a comparative non-randomized study
by: Arfenya E. Karamova, et al.
Published: (2025-06-01) -
Impact of Treatment Interruption on the Effectiveness of Interleukin (IL)-17A Inhibitors in Plaque Psoriasis: A Retrospective Analysis
by: Jiang J, et al.
Published: (2025-03-01) -
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
by: Luciano Ibba, et al.
Published: (2024-12-01) -
Aspectos de la IL-17 en la inmunopatogénesis de la psoriasis: un nuevo blanco terapéutico
by: Luis Carlos Ramírez, et al.
Published: (2019-08-01) -
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
by: Susanne Klint, et al.
Published: (2023-12-01)